Endometriosis and Migraine
NCT06785129
Recruiting
This study aims to determine differences in experimental pain and sex hormone levels between patients with migraine, patients with endometriosis, patients with migraine and endometriosis, and healthy controls. Participants will complete surveys, experimental pain paradigms and collection of samples for hormone analyses.
Gender:
FEMALE
Ages:
Between 12 years and 45 years
Trial Updated:
08/11/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Migraine, Endometriosis
Register for Updates
Assessment of Morbidity and Mortality Following Serratus Anterior Plane Block (SAPB) for Unilateral Rib Fractures
NCT07032766
Recruiting
The goal of this observational study is to learn about the long-term effects of the serratus anterior plane block (SAPB) in adult patients who suffered multiple unilateral anterolateral rib fractures within 24 hours of patient presentation to the emergency department. The main question it aims to answer is: Does the SAPB for multiple anterolateral rib fractures demonstrate reduction in patient morbidity and mortality, including incidence of pneumonia, length of hospital stay, discharge disposit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Jacobi Medical Center, Bronx, New York
Conditions: Pain Management, Rib Fracture Multiple, Serratus Anterior Plane Block
Register for Updates
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961
Recruiting
The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Dermatology Research Associate, Los Angeles, California +33 locations
Conditions: Atopic Dermatitis
Register for Updates
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
NCT06653842
Recruiting
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Gender:
ALL
Ages:
6 years and above
Trial Updated:
08/11/2025
Locations: Children's Hospital of Orange County, Irvine, California +9 locations
Conditions: Cutaneous Venous Malformations
Register for Updates
A Study of Dotinurad Versus Allopurinol in Participants With Gout
NCT07089875
Recruiting
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/11/2025
Locations: Pioneer Research Solutions, Houston, Texas
Conditions: Gout
Register for Updates
Improving Communication Between AYA Oncology Patients and Clinicians: A Patient-Centered Intervention
NCT06982066
Recruiting
The overarching goal is to develop and demonstrate proof-of-concept of ReSPECT (Reproductive and Sexual Health Patient Education and Communication Tool), a multi-modal communication intervention to improve adolescent and young adult (AYA)- clinician sexual and reproductive health (SRH) communication in the outpatient oncology clinic setting.
Gender:
ALL
Ages:
Between 15 years and 25 years
Trial Updated:
08/11/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Pediatric Cancer, Adolescent and Young Adult Cancer
Register for Updates
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
NCT05763121
Recruiting
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
08/11/2025
Locations: Research Site 20001-374, Bakersfield, California +385 locations
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Register for Updates
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
NCT05849298
Recruiting
The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium \[177Lu\] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive, castration-resistant prostate cancer and no evidence of metastasis in conventional imaging (CI) (i.e., CT/MRI and bone scans). Approximately 80 participants will be randomized.
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
08/11/2025
Locations: Urology Associates of Mobile, Mobile, Alabama +49 locations
Conditions: Prostatic Neoplasm
Register for Updates
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391
Recruiting
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
08/11/2025
Locations: University of Alabama, Birmingham, Alabama +44 locations
Conditions: Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes
Register for Updates
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362
Recruiting
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
Gender:
ALL
Ages:
Between 40 years and 84 years
Trial Updated:
08/10/2025
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +90 locations
Conditions: Heart Failure
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
NCT06542874
Recruiting
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/10/2025
Locations: Southern Cal Clinical Research, Santa Ana, California +178 locations
Conditions: Type 2 Diabetes (T2D)
Register for Updates
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
NCT06858397
Recruiting
This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: David Geffen School of Medicine UCLA, UCLA Health, Los Angeles, California +9 locations
Conditions: Fabry Disesase
Register for Updates